July 6, 2020
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
It should be outlined, that Quantitative Systems Pharmacology (QSP) is a discipline that uses mathematical computer models to characterize biological systems, to determine the optimal doses, target groups of patients and substances effect on the human body. QSP typically functions through mechanism-based dynamical models described by ODE systems. Therefore, the modeling systems may include hundreds or thousands of components and are developed by a research group involving people with different expertise. Evgeny Metelkin, Head of InSysBio product development, highlights: “Heta compiler can be used as the framework for a QSP modeling project of any size and complexity. It can be easily integrated with existed infrastructure, workflows or used as a part of the CI/CD strategy”.
Actually, Heta compiler is a tool that allows to perform a number of functions, namely:
Heta compiler is developed as Free Open Source project published on GitHub. The actual version of Heta compiler is 0.5.3, which supports Heta language of version 0.3.1.
Heta compiler is written in JаvaScript/Node language and is distributed as a npm package. This software can work in command line tool mode or may be used as a package for browser or server-side tools and applications.
Heta compiler has already supported the fulfillment of a number of InSysBio projects, namely:
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
← | September 2020 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
|
5
|
6
| |
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|